drug
amisulpride
Marketedupdated 3mo agoby Acacia Pharma Group Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying amisulpride
- phase3Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients
- phase1Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
- N/AAn Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms
- phase1Effects of a Single Dose of Amisulpride on Functional Brain Changes
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 10, 2031
~4.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Feb 9, 2038method-of-use (U-2754)US 11357753
- Feb 9, 2038method-of-use (U-2754)US 11357753
- Feb 9, 2038method-of-use (U-1744)US 12005042
- Feb 9, 2038method-of-use (U-2754)US 12005042
- Feb 9, 2038method-of-use (U-3467)US 12329740
- Feb 9, 2038method-of-use (U-3467)US 12329740
- Feb 26, 2034method-of-use (U-3467)US 9084765
- Feb 26, 2034method-of-use (U-3467)US 9084765
- Mar 10, 2031formulationUS 105250334.6y
- Mar 10, 2031formulationUS 105250334.6y
- Mar 10, 2031method-of-use (U-3467)US 121940224.6y
- Mar 10, 2031method-of-use (U-3467)US 121940224.6y
- Mar 10, 2031method-of-use (U-2754)US 95454264.6y
- Mar 10, 2031method-of-use (U-1744)US 95454264.6y
- Mar 10, 2031method-of-use (U-1744)US 98891184.6y
- Mar 10, 2031method-of-use (U-1744)US 98891184.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that